Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9538 |
Name | multiple myeloma |
Definition | A myeloid neoplasm that is located_in the plasma cells in bone marrow. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00734877 | Phase III | Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide Bortezomib + Dexamethasone + Melphalan + Thalidomide | UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma | Active, not recruiting | USA | 0 |
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT00903968 | Phase Ib/II | Bortezomib + Plerixafor | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT00918333 | Phase Ib/II | Everolimus + Panobinostat | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Completed | USA | TUR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | BRA | BEL | ARG | 5 |
NCT01146834 | Phase III | Bortezomib + Filgrastim Bortezomib + Cyclophosphamide + Filgrastim Bortezomib + Cyclophosphamide | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | Completed | USA | 0 |
NCT01163357 | Phase I | Sirolimus Bortezomib + Fludarabine + Melphalan | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01177683 | Phase Ib/II | Bendamustine + Bortezomib + Pegylated liposomal doxorubicin Filgrastim | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | Terminated | USA | 0 |
NCT01208662 | Phase III | Bortezomib + Dexamethasone + Lenalidomide | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106) | Active, not recruiting | USA | 0 |
NCT01239368 | Phase I | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | Terminated | USA | 0 | |
NCT01241708 | Phase III | Bortezomib | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)) | Completed | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01287546 | Phase I | Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab | A Study of LY2875358 in Participants With Advanced Cancer | Completed | USA | 0 |
NCT01301807 | Phase I | Carfilzomib + Panobinostat | Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM) | Completed | USA | 0 |
NCT01313897 | Phase II | Bortezomib | UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35) | Completed | USA | 0 |
NCT01323751 | Phase Ib/II | Bortezomib + Dexamethasone Ricolinostat | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
NCT01326702 | Phase Ib/II | Veliparib Rituximab Bendamustine | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Completed | USA | 0 |
NCT01345019 | Phase III | Denosumab Zoledronic acid | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma | Completed | USA | TUR | SVK | POL | NZL | LTU | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | AUT | AUS | 9 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01428492 | Phase I | Afuresertib Bortezomib Dexamethasone | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | IRL | CAN | AUS | 1 |
NCT01440582 | Phase I | Bortezomib + Dexamethasone + Lenalidomide + Panobinostat | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | Completed | USA | 0 |
NCT01453088 | Phase II | Melphalan Bortezomib | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | Terminated | USA | 0 |
NCT01453101 | Phase II | Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Completed | USA | 0 |
NCT01456689 | Phase I | Midazolam LGH447 | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | ESP | DEU | 1 |
NCT01470131 | Phase III | Masitinib Bortezomib + Dexamethasone | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | Terminated | USA | FRA | 0 |
NCT01522872 | Phase Ib/II | Evofosfamide Bortezomib | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma | Unknown status | USA | 0 |
NCT01524978 | Phase II | Vemurafenib Cetuximab | A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT01526096 | Phase I | Basiliximab Filgrastim Plerixafor Melphalan | Stem Cell Transplantation for Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01547806 | Phase II | Filgrastim Plerixafor | Collection of Transplant Stem Cells for Plasma Cell Myeloma | Completed | USA | 0 |
NCT01582295 | Phase I | Cabozantinib | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01592370 | Phase Ib/II | Nivolumab Daratumumab + Nivolumab Daratumumab Ipilimumab + Nivolumab Daratumumab + Dexamethasone + Nivolumab + Pomalidomide Lirilumab + Nivolumab | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Completed | USA | POL | ITA | GRC | FRA | BEL | 0 |
NCT01609816 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT01665794 | Phase Ib/II | Carfilzomib + Dexamethasone + Pomalidomide Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT01668719 | Phase Ib/II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01672736 | Phase Ib/II | Bortezomib + Dexamethasone + Linsitinib | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | Terminated | USA | CAN | 0 |
NCT01689987 | Phase I | Cyclophosphamide + Dexamethasone + Hydroxychloroquine + Sirolimus | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT01695330 | Phase II | Bortezomib | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | Terminated | USA | 0 |
NCT01711528 | Phase I | Bortezomib + Dexamethasone + Dinaciclib | Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Completed | USA | 0 |
NCT01723020 | Phase I | KRT-232 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | Completed | USA | NLD | FRA | 0 |
NCT01729091 | Phase Ib/II | Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide | Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma | Completed | USA | 0 |
NCT01729338 | Phase II | Bortezomib + Cyclophosphamide + Lenalidomide | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Terminated | USA | 0 |
NCT01734928 | Phase III | Pomalidomide Bortezomib + Dexamethasone | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | 4 |
NCT01794507 | Phase I | Bortezomib + Dexamethasone + Venetoclax | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Completed | USA | FRA | AUS | 0 |
NCT01794520 | Phase I | Venetoclax | Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma | Completed | USA | NOR | FRA | BEL | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01827137 | Phase I | WT1 vaccine Lenalidomide Sargramostim | WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01849783 | Phase II | Bortezomib + Dexamethasone + Melphalan + Thalidomide Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | Completed | USA | 0 |
NCT01863550 | Phase III | Dexamethasone Lenalidomide Carfilzomib Bortezomib | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 1 |
NCT01866293 | Phase Ib/II | Cabozantinib | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | Completed | USA | 0 |
NCT01889420 | Phase I | Dexamethasone + Everolimus + Pomalidomide | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT01919086 | Phase II | Lenalidomide Bortezomib + Dexamethasone | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | Completed | USA | 0 |
NCT01947140 | Phase Ib/II | Pralatrexate + Romidepsin | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) | Completed | USA | 0 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01954784 | Phase I | Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma | Terminated | USA | 0 |
NCT01955434 | Phase II | Cyclophosphamide + LCL161 | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT01962792 | Phase Ib/II | Carfilzomib + Ibrutinib Dexamethasone | Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | Completed | USA | CAN | 0 |
NCT01965353 | Phase I | Bortezomib + Dexamethasone + Lenalidomide + Panobinostat | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT01989598 | Phase II | Trametinib + Uprosertib | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | CAN | 0 |
NCT01995708 | Phase I | CT7/MAGE-A3/WT1 mRNA-electroporated LCs | CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | Completed | USA | 0 |
NCT01997840 | Phase Ib/II | Dexamethasone + Pomalidomide + Ricolinostat | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT01998971 | Phase I | Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | Completed | USA | FRA | ESP | 0 |
NCT02030483 | Phase I | Palbociclib Dexamethasone Lenalidomide | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | Terminated | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | SWE | NOR | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 2 |
NCT02036502 | Phase I | Dexamethasone Lenalidomide + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | Terminated | 0 | |
NCT02057640 | Phase Ib/II | Dexamethasone + Ixazomib + Panobinostat | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02077959 | Phase Ib/II | Lenalidomide + Pidilizumab | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02086552 | Phase II | Lenalidomide + Sonidegib | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Completed | USA | 0 |
NCT02098109 | Phase II | Plerixafor Filgrastim | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02099539 | Phase Ib/II | Nogapendekin alfa inbakicept | A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02101944 | Phase I | Carfilzomib + Dexamethasone + Pelareorep | Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma | Completed | USA | 0 |
NCT02104427 | Phase II | Burixafor Filgrastim | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Completed | USA | 0 |
NCT02110563 | Phase I | DCR-MYC | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | Terminated | USA | 0 |
NCT02136134 | Phase III | Daratumumab Bortezomib + Dexamethasone | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | Completed | USA | TUR | SWE | POL | NLD | HUN | ESP | DEU | CZE | BRA | AUS | 4 |
NCT02140840 | Phase II | Trametinib | A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | Withdrawn | USA | 0 |
NCT02144038 | Phase Ib/II | Alpelisib + LGH447 LGH447 | Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | Completed | USA | ITA | DEU | AUS | 1 |
NCT02157636 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | Completed | 0 | |
NCT02159365 | Phase II | Dexamethasone + Elotuzumab + Lenalidomide | Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | Completed | USA | 0 |
NCT02186834 | Phase Ib/II | Dexamethasone + Pegylated liposomal doxorubicin + Selinexor | Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02188368 | Phase II | Bortezomib + Carfilzomib + Clarithromycin Pegylated liposomal doxorubicin + Pomalidomide Pomalidomide | Pomalidomide for Lenalidomide for Failures | Terminated | USA | 0 |
NCT02189343 | Phase I | Dexamethasone + Pomalidomide + Ricolinostat | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02192775 | Phase II | MV-NIS | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | Completed | USA | 0 |
NCT02195479 | Phase III | Bortezomib Daratumumab Melphalan | A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | Completed | USA | TUR | ROU | POL | HUN | HRV | GRC | GBR | ESP | DEU | CZE | BRA | BGR | BEL | AUS | ARG | 8 |
NCT02199665 | Phase I | Carfilzomib + Dexamethasone + Selinexor | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT02204553 | Phase I | Bortezomib + Dexamethasone + Panobinostat | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | No longer available | USA | 0 |
NCT02211014 | Phase I | Acalabrutinib Dexamethasone | An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | GBR | 0 |
NCT02220608 | Phase I | Bortezomib + Filgrastim | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | Completed | USA | 0 |
NCT02223598 | Phase I | CB-5083 CB-5083 + Dexamethasone | A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) | Terminated | USA | CAN | 0 |
NCT02235740 | Phase I | Carfilzomib Afuresertib + Carfilzomib | A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | Terminated | USA | 0 |
NCT02252263 | Phase I | Urelumab Lirilumab Elotuzumab | A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma | Completed | USA | ESP | 0 |
NCT02254551 | Phase II | Bortezomib + Sonidegib | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02283775 | Phase I | Dexamethasone + Isatuximab + Pomalidomide | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR) | Completed | USA | 0 |
NCT02289222 | Phase Ib/II | Dexamethasone + Pembrolizumab + Pomalidomide | Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02291848 | Phase I | MultiTAA-specific T cells | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM) | Recruiting | USA | 0 |
NCT02308280 | Phase II | Bortezomib | Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | Completed | CAN | 0 |
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02331368 | Phase II | Lenalidomide Melphalan Pembrolizumab | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | Completed | USA | 0 |
NCT02332850 | Phase I | Carfilzomib + Isatuximab | SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT02334865 | Phase I | Lenalidomide + Montanide ISA 51 + Sargramostim + SurVaxM | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | Active, not recruiting | USA | 0 |
NCT02336815 | Phase II | Dexamethasone + Selinexor | Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies | Completed | USA | GRC | FRA | DEU | BEL | AUT | 0 |
NCT02343042 | Phase Ib/II | Bortezomib Dexamethasone + Selinexor Pomalidomide | Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02367196 | Phase I | CC-90002 + Rituximab CC-90002 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | Completed | USA | ESP | 0 |
NCT02368301 | Phase I | Dexamethasone + Elotuzumab + Lenalidomide | Expanded Access Treatment Protocol CA204-143 | No longer available | 0 | |
NCT02372240 | Phase Ib/II | Dexamethasone + VLX1570 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | Terminated | USA | 0 |
NCT02375555 | Phase II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | Completed | USA | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
NCT02400242 | Phase I | Citarinostat Dexamethasone Pomalidomide | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | Terminated | USA | GRC | FRA | ESP | DEU | 0 |
NCT02401295 | Phase I | Celecoxib + Itraconazole + Tretinoin | ATRA, Celecoxib, and Itraconazole as Maintenance | Completed | USA | 0 |
NCT02407509 | Phase I | RO5126766 Everolimus + RO5126766 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK) | Recruiting | GBR | 0 |
NCT02426723 | Phase I | CWP232291 Dexamethasone + Lenalidomide | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | Completed | USA | 1 |
NCT02431208 | Phase I | Lenalidomide Atezolizumab | A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) | Completed | USA | 0 |
NCT02440464 | Phase II | Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | Completed | USA | 0 |
NCT02441686 | Phase II | Bortezomib + Dexamethasone + Lenalidomide | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02465060 | Phase II | Nivolumab + Relatlimab Dabrafenib + Trametinib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02504359 | Phase I | Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Methotrexate + Tacrolimus | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | Completed | USA | 0 |
NCT02514382 | Phase I | Bortezomib + Dexamethasone + Pelareorep | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02514668 | Phase I | Isatuximab | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | Completed | USA | FRA | CZE | 0 |
NCT02519452 | Phase I | Daratumumab + rHuPH20 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | Completed | USA | SWE | NLD | FRA | ESP | DNK | 0 |
NCT02548962 | Phase Ib/II | Ibrutinib Dexamethasone + Pomalidomide | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | Terminated | USA | GRC | ESP | DEU | CZE | AUS | 0 |
NCT02568943 | Phase I | Bortezomib + Dexamethasone + Panobinostat | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | No longer available | SWE | NOR | DEU | CAN | AUT | 1 |
NCT02569320 | Phase I | Dexamethasone + Pomalidomide + REC-2282 | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | Completed | USA | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02576977 | Phase III | Pomalidomide Pembrolizumab Dexamethasone | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | Terminated | 0 | |
NCT02579824 | Phase I | Milademetan | DS-3032b for Relapsed and/or Refractory (RR) Myeloma | Terminated | USA | 0 |
NCT02579863 | Phase III | Pembrolizumab Dexamethasone Lenalidomide | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | Terminated | 0 | |
NCT02603887 | Phase I | Pembrolizumab | Pembrolizumab for Smoldering Multiple Myeloma (SMM) | Active, not recruiting | USA | 0 |
NCT02605356 | Phase Ib/II | Radium Ra 223 dichloride Bortezomib Dexamethasone | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | Withdrawn | USA | ITA | ISR | GRC | ESP | DEU | CAN | BEL | AUS | 2 |
NCT02609230 | Phase I | ONC201 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | Completed | USA | 0 |
NCT02612779 | Phase II | Dexamethasone + Elotuzumab + Pomalidomide | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide | Completed | USA | 0 |
NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT02628704 | Phase II | Carfilzomib + Dexamethasone + Selinexor | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | Withdrawn | USA | 0 |
NCT02633059 | Phase Ib/II | Dexamethasone + Idasanutlin + Ixazomib | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Completed | USA | 0 |
NCT02649790 | Phase Ib/II | Eltanexor | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02654132 | Phase II | Dexamethasone + Pomalidomide Elotuzumab | Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma | Completed | USA | POL | NLD | ITA | GRC | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02654990 | Phase II | Bortezomib + Dexamethasone + Panobinostat | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma | Completed | USA | TUR | SWE | POL | NOR | NLD | LBN | ITA | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 4 |
NCT02655458 | Phase I | Elotuzumab + Lenalidomide | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | Completed | USA | 0 |
NCT02658396 | Phase I | Bortezomib + GO-203-2C | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | Withdrawn | USA | 0 |
NCT02658929 | Phase I | Idecabtagene Vicleucel | Study of bb2121 in Multiple Myeloma | Completed | USA | 0 |
NCT02666209 | Phase I | Bortezomib + Dexamethasone + Ulocuplumab Dexamethasone + Lenalidomide + Ulocuplumab | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | No longer available | USA | 0 |
NCT02675452 | Phase I | AMG 176 | AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | DEU | CAN | AUS | 1 |
NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Terminated | USA | 0 |
NCT02684617 | Phase I | Dinaciclib + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) | Terminated | 0 | |
NCT02685826 | Phase I | Dexamethasone Durvalumab + Lenalidomide | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma | Completed | USA | NLD | ITA | FIN | ESP | DNK | DEU | CAN | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT02700841 | Phase II | Melphalan + PVX-410 | Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation | Terminated | USA | 0 |
NCT02703779 | Phase II | Bortezomib Filgrastim + Plerixafor | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | Completed | USA | 0 |
NCT02716805 | Phase I | Durvalumab + Tremelimumab | Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT02718833 | Phase II | Bortezomib + Dexamethasone + Elotuzumab + Panobinostat | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02719613 | Phase II | Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide | Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | Active, not recruiting | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | ESP | CAN | BEL | AUS | 1 |
NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02722941 | Phase II | Panobinostat | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | Completed | USA | 0 |
NCT02726581 | Phase III | Elotuzumab Nivolumab Dexamethasone + Pomalidomide | Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma | Completed | USA | TUR | SWE | NOR | ITA | ISR | GRC | ESP | DNK | DEU | CZE | CHE | CAN | AUT | 2 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02755597 | Phase III | Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Completed | USA | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT02757326 | Phase Ib/II | ABC294640 | ABC294640 in Refractory / Relapsed Multiple Myeloma | Terminated | USA | 0 |
NCT02765854 | Phase II | Dexamethasone + Ixazomib + Lenalidomide Dexamethasone + Ixazomib | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | Active, not recruiting | USA | 0 |
NCT02773030 | Phase Ib/II | Iberdomide Dexamethasone + Iberdomide Daratumumab + Dexamethasone + Iberdomide Bortezomib + Dexamethasone + Iberdomide | A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02780609 | Phase Ib/II | Dexamethasone + Melphalan + Selinexor | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | Completed | USA | 0 |
NCT02784483 | Phase I | Atezolizumab | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | Terminated | USA | 0 |
NCT02786485 | Phase I | Rimiducid Rivogenlecleucel | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02802163 | Phase Ib/II | Carfilzomib + Dexamethasone + Lenalidomide + Panobinostat | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | Withdrawn | 0 | |
NCT02807454 | Phase Ib/II | Daratumumab + Dexamethasone + Durvalumab + Pomalidomide Daratumumab + Durvalumab | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) | Terminated | USA | SWE | ITA | GBR | ESP | DNK | DEU | CAN | BEL | 0 |
NCT02831686 | Phase I | Dexamethasone + Ixazomib + Selinexor | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | Completed | USA | 0 |
NCT02833610 | Phase II | Denosumab | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | Unknown status | USA | 0 |
NCT02851056 | Phase I | Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | Completed | USA | 0 |
NCT02863991 | Phase II | ONC201 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02874742 | Phase II | Daratumumab Bortezomib + Dexamethasone + Lenalidomide | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | Completed | USA | 0 |
NCT02880228 | Phase II | Dexamethasone + Lenalidomide + Pembrolizumab | Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | Completed | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02891811 | Phase II | Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Thalidomide | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | Completed | DEU | AUT | 0 |
NCT02899052 | Phase II | Carfilzomib + Dexamethasone + Venetoclax | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | HUN | ESP | AUS | 1 |
NCT02906332 | Phase II | Pembrolizumab Dexamethasone | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | Terminated | USA | 0 |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT02928029 | Phase Ib/II | Bortezomib + Dexamethasone + Radium Ra 223 dichloride | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Terminated | USA | ESP | 1 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02943473 | Phase II | Ibrutinib | Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | Terminated | USA | 0 |
NCT02948283 | Phase 0 | Metformin + Ritonavir | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02951819 | Phase II | Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | Completed | USA | 0 |
NCT02952573 | Phase II | Dexamethasone + Erdafitinib | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement | Terminated | CAN | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02963493 | Phase II | Dexamethasone + Melflufen | A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON) | Completed | USA | ITA | FRA | ESP | 0 |
NCT02978235 | Phase Ib/II | TAS4464 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | Terminated | USA | 0 |
NCT02990338 | Phase III | Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Pomalidomide | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM) | Completed | USA | TUR | SWE | SVK | POL | NZL | NOR | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
NCT02992483 | Phase I | MIK665 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT02998047 | Phase I | Lintuzumab-Ac225 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03000452 | Phase II | Daratumumab + Durvalumab | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005) | Completed | USA | SWE | NLD | GRC | ESP | AUT | 0 |
NCT03003728 | Phase II | Elotuzumab + Melphalan + Nogapendekin alfa inbakicept | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | Withdrawn | USA | 0 |
NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
NCT03015792 | Phase Ib/II | Dexamethasone + Ibrutinib + Lenalidomide | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | Terminated | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03019666 | Phase I | Allogeneic NAM NK cells Cyclophosphamide + Fludarabine | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Completed | USA | 0 |
NCT03030261 | Phase II | Melphalan Dexamethasone + Elotuzumab + Pomalidomide | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT03031730 | Phase I | Carfilzomib + Dexamethasone + KRT-232 + Lenalidomide | MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03068351 | Phase I | TEN-010 Daratumumab + TEN-010 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | Completed | USA | GBR | AUS | 0 |
NCT03091257 | Phase I | Dabrafenib + Trametinib Dabrafenib Trametinib | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03104270 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Pomalidomide | Combination Study for High Risk Multiple Myeloma Patients | Terminated | USA | 0 |
NCT03104842 | Phase II | Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide | Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | Active, not recruiting | DEU | 0 |
NCT03106428 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | Completed | USA | FRA | 1 |
NCT03110562 | Phase III | Bortezomib + Dexamethasone + Selinexor Bortezomib + Dexamethasone | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) | Completed | USA | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 4 |
NCT03110822 | Phase I | Lenalidomide + Methylprednisolone + Ruxolitinib | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Recruiting | USA | 0 |
NCT03111992 | Phase I | LCL161 + Spartalizumab CJM112 + Spartalizumab Spartalizumab | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | Completed | USA | ITA | ESP | DEU | 0 |
NCT03143985 | Phase I | Pomalidomide + Vactosertib | TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03145181 | Phase I | Teclistamab | Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | SWE | NLD | FRA | ESP | 0 |
NCT03151811 | Phase III | Dexamethasone + Pomalidomide Dexamethasone + Melflufen | A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) | Terminated | USA | ROU | POL | NOR | NLD | LTU | ITA | ISR | HUN | GRC | GBR | FRA | EST | ESP | DNK | CZE | BEL | AUT | 3 |
NCT03168100 | Phase II | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | Withdrawn | USA | 0 |
NCT03168438 | Phase II | Letetresgene autoleucel Letetresgene autoleucel + Pembrolizumab | Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | Terminated | USA | 0 |
NCT03194867 | Phase Ib/II | Cemiplimab + Isatuximab | Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Completed | USA | ITA | HUN | GRC | FRA | ESP | CZE | CAN | BRA | AUS | 0 |
NCT03201250 | Phase Ib/II | Cabozantinib + Carfilzomib + Dexamethasone | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03215030 | Phase Ib/II | Dexamethasone + TAK-573 TAK-573 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | TUR | NOR | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | 5 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03221634 | Phase II | Daratumumab + Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | Withdrawn | USA | SWE | ISR | FRA | ESP | CAN | 0 |
NCT03227432 | Phase II | Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide Elotuzumab + Nivolumab | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03246529 | Phase III | Filgrastim BKT140 + Filgrastim | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) | Active, not recruiting | USA | ITA | HUN | ESP | DEU | 0 |
NCT03256045 | Phase II | Carfilzomib + Dexamethasone + Panobinostat | Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03266692 | Phase I | ACTR087 + SEA-BCMA | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03267888 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03269136 | Phase I | Elranatamab-bcmm | Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma | Completed | USA | CAN | 0 |
NCT03275103 | Phase I | Cevostamab | Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | Recruiting | USA | ESP | CAN | AUS | 0 |
NCT03275285 | Phase III | Carfilzomib + Dexamethasone + Isatuximab Carfilzomib + Dexamethasone | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) | Active, not recruiting | USA | TUR | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE | CAN | BRA | AUS | 3 |
NCT03287908 | Phase I | AMG 701 | A Phase 1/2 Study of AMG 701 in Subjects With Multiple Myeloma | Terminated | USA | NLD | DEU | CAN | AUS | 1 |
NCT03288480 | Phase I | Imifoplatin | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03288493 | Phase I | P-BCMA-101 CAR-T cells | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Terminated | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT03309111 | Phase I | ISB 1342 | Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | Completed | USA | FRA | 0 |
NCT03314181 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Venetoclax | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | FRA | DNK | DEU | CAN | AUS | 1 |
NCT03315026 | Phase II | Siltuximab | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | Active, not recruiting | USA | 0 |
NCT03319667 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) | Active, not recruiting | USA | TUR | SWE | POL | NZL | LTU | ITA | GRC | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 6 |
NCT03333746 | Phase II | Lenalidomide + Nivolumab | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03338972 | Phase I | Cyclophosphamide + Fludarabine Anti-BCMA CAR-T cells | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03346135 | Phase II | Melphalan Daratumumab | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03352765 | Phase I | Bendamustine + Melphalan + Rituximab | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | Active, not recruiting | USA | 0 |
NCT03357952 | Phase I | Cetrelimab + Daratumumab | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | Completed | ISR | ESP | BEL | 0 |
NCT03361306 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M | Active, not recruiting | USA | 0 |
NCT03361748 | Phase II | Idecabtagene Vicleucel | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 1 |
NCT03374085 | Phase I | CC-92480 + Dexamethasone | A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | GRC | GBR | FIN | ESP | DNK | CAN | BEL | AUS | 2 |
NCT03399799 | Phase I | Talquetamab-tgvs | Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | NLD | ESP | BEL | 0 |
NCT03411031 | Phase II | Elotuzumab + Lenalidomide Dexamethasone | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | Terminated | USA | 0 |
NCT03412565 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | Completed | USA | ISR | GBR | FRA | ESP | DEU | CZE | BRA | 1 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03428373 | Phase II | Dexamethasone + Lenalidomide + Rivaroxaban Aspirin + Dexamethasone + Lenalidomide | ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy. (RithMM) | Active, not recruiting | CAN | 0 |
NCT03439280 | Phase Ib/II | Dexamethasone + Mezagitamab + Pomalidomide Mezagitamab | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | Completed | USA | 0 |
NCT03441958 | Phase Ib/II | Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | Active, not recruiting | CAN | 0 |
NCT03457142 | Phase II | BMS-188667 + Dexamethasone + Ixazomib | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | Active, not recruiting | USA | 0 |
NCT03464916 | Phase I | CAR2 anti-CD38 A2 CAR T cells | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | Completed | USA | 0 |
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Terminated | USA | ITA | GRC | FRA | AUS | 1 |
NCT03477539 | Phase II | Daratumumab + Lenalidomide Daratumumab | Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03481556 | Phase Ib/II | Bortezomib + Dexamethasone + Melflufen Daratumumab + Dexamethasone + Melflufen | Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR) | Terminated | USA | FRA | ESP | CZE | 0 |
NCT03486067 | Phase I | CC-93269 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | SWE | ITA | ESP | DEU | 1 |
NCT03489525 | Phase I | MEDI2228 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) | Completed | USA | GRC | ESP | AUS | 0 |
NCT03490344 | Phase II | Daratumumab + Lenalidomide | Short Course Daratumumab in Patients With Multiple Myeloma | Completed | USA | 0 |
NCT03492138 | Phase Ib/II | Dexamethasone + Ixazomib + ONC201 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03500445 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03502577 | Phase I | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine + LY3039478 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | Terminated | USA | 0 |
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
NCT03506360 | Phase II | Dexamethasone + Ixazomib + Pembrolizumab | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma | Completed | USA | 0 |
NCT03506802 | Phase I | Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03525678 | Phase II | belantamab mafodotin-blmf | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 0 |
NCT03530683 | Phase I | TTI-622 | A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma | Terminated | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03539744 | Phase III | Dexamethasone + Pomalidomide Dexamethasone + Venetoclax | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA) | Active, not recruiting | USA | TUR | SWE | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | AUS | 6 |
NCT03544281 | Phase II | belantamab mafodotin-blmf + Bortezomib + Dexamethasone belantamab mafodotin-blmf + Dexamethasone + Lenalidomide | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | Completed | USA | GBR | ESP | CAN | AUS | 0 |
NCT03548207 | Phase Ib/II | Ciltacabtagene autoleucel | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Completed | USA | 1 |
NCT03556332 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03567616 | Phase II | Dexamethasone + Pomalidomide + Venetoclax | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Terminated | USA | GBR | ESP | 0 |
NCT03582033 | Phase I | SEA-BCMA | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Terminated | USA | 0 |
NCT03589222 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Selinexor | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | Unknown status | ESP | 0 |
NCT03591614 | Phase I | DKK1 dendritic cell vaccine | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | Withdrawn | USA | 0 |
NCT03601078 | Phase II | Idecabtagene Vicleucel | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03602612 | Phase I | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03605719 | Phase I | Carfilzomib + Dexamethasone + Nivolumab + Pelareorep Carfilzomib + Dexamethasone + Nivolumab | Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03607643 | Phase Ib/II | Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Unknown status | USA | 0 |
NCT03622775 | Phase II | Daratumumab | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT03634800 | Phase II | Nivolumab | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) | Terminated | USA | 0 |
NCT03650491 | Phase I | FOR46 | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | Completed | USA | 0 |
NCT03651128 | Phase III | Bortezomib + Daratumumab + Dexamethasone Idecabtagene Vicleucel Dexamethasone + Ixazomib + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide | Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 1 |
NCT03652064 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Active, not recruiting | USA | TUR | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | 1 |
NCT03657420 | Phase I | Dexamethasone + Nab-rapamycin + Pomalidomide | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03669445 | Phase II | Daratumumab + Dexamethasone + Ixazomib + Lenalidomide | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma (IFM2018-01) | Recruiting | FRA | 0 |
NCT03672318 | Phase I | ATLCAR.CD138 + Cyclophosphamide + Fludarabine | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03687125 | Phase Ib/II | Tinostamustine | Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1) | Terminated | USA | NOR | CHE | 0 |
NCT03701321 | Phase Ib/II | Bortezomib + Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone + Venetoclax | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03702725 | Phase I | Dexamethasone + Ibrutinib + Lenalidomide | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03710421 | Phase I | CS1-CAR T cells + Cyclophosphamide + Fludarabine | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | Recruiting | USA | 0 |
NCT03713294 | Phase II | Dexamethasone + Elotuzumab + Pomalidomide | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03715478 | Phase Ib/II | belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Active, not recruiting | CAN | 0 |
NCT03729804 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Lenalidomide | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA)) | Active, not recruiting | USA | 0 |
NCT03732703 | Phase Ib/II | Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide | Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) | Unknown status | USA | 0 |
NCT03741127 | Phase I | Rimiducid | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | Active, not recruiting | USA | 0 |
NCT03742297 | Phase III | Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide + Melphalan + Prednisone | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | Active, not recruiting | ESP | 0 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03757221 | Phase II | Daratumumab + Ixazomib | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma (IDARA) | Recruiting | FRA | 0 |
NCT03761108 | Phase Ib/II | Linvoseltamab | First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | GBR | ESP | DEU | BEL | 2 |
NCT03763162 | Phase II | Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Ixazomib | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03770260 | Phase I | Ixazomib + MLN4924 | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | Completed | USA | 0 |
NCT03773107 | Phase Ib/II | Carfilzomib + Dexamethasone + Ruxolitinib | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03782064 | Phase II | DC myeloma fusion vaccine + Nivolumab | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | Terminated | USA | 0 |
NCT03785184 | Phase II | Dexamethasone + Lenalidomide + Venetoclax | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | Withdrawn | USA | ESP | CAN | AUS | 0 |
NCT03829020 | Phase I | Metformin + Nelfinavir Bortezomib + Metformin + Nelfinavir | Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT03829371 | FDA approved | Dexamethasone + Lenalidomide Bortezomib + Melphalan + Prednisone | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | Recruiting | ITA | 0 |
NCT03837509 | Phase Ib/II | Daratumumab + INCB001158 Daratumumab | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | Terminated | USA | ESP | DEU | 0 |
NCT03841565 | Phase II | Daratumumab + Dexamethasone + Pomalidomide | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Withdrawn | USA | 0 |
NCT03848845 | Phase II | belantamab mafodotin-blmf + Pembrolizumab | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4) | Completed | USA | ESP | DEU | CAN | 0 |
NCT03859427 | Phase III | Carfilzomib + Dexamethasone + Lenalidomide | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2) | Completed | USA | TUR | SWE | SVK | ROU | NLD | LTU | GRC | FRA | FIN | ESP | DEU | CZE | BGR | AUT | 2 |
NCT03871829 | Phase II | Carfilzomib + Daratumumab + Dexamethasone Carfilzomib + Dexamethasone | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | Terminated | USA | POL | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 1 |
NCT03896737 | Phase II | Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone Ixazomib Bortezomib + Dexamethasone + Thalidomide Daratumumab + Ixazomib | Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | Active, not recruiting | ITA | GRC | CZE | 0 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Unknown status | AUS | 0 |
NCT03901963 | Phase III | Daratumumab + Lenalidomide Lenalidomide | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA) | Active, not recruiting | USA | CAN | 0 |
NCT03910439 | Phase II | Avelumab | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03915184 | Phase I | Anti-BCMA CAR-T cells | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT03933735 | Phase I | ABBV-383 | A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | DEU | 0 |
NCT03937635 | Phase III | Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Recruiting | USA | 1 |
NCT03942224 | Phase II | Daratumumab + Dexamethasone + Ixazomib Bortezomib + Daratumumab + Dexamethasone | Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) | Active, not recruiting | USA | 0 |
NCT03948035 | Phase III | Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | Active, not recruiting | DEU | AUT | 0 |
NCT03958656 | Phase I | Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | Completed | USA | 0 |
NCT03984097 | Phase I | Dexamethasone + Lenalidomide + Mezagitamab Bortezomib + Dexamethasone + Lenalidomide + Mezagitamab | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | Active, not recruiting | USA | 0 |
NCT03989414 | Phase Ib/II | Bortezomib + CC-92480 + Dexamethasone CC-92480 + Daratumumab + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone | A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | Active, not recruiting | USA | ITA | GRC | FRA | ESP | DNK | DEU | CZE | CAN | 0 |
NCT03992170 | Phase II | Daratumumab | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM) | Unknown status | ITA | 0 |
NCT03993912 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide | Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03) | Active, not recruiting | FRA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04000282 | Phase I | SAR442085 | First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | Completed | USA | GRC | FRA | ESP | CZE | 1 |
NCT04009109 | Phase II | Daratumumab + Dexamethasone + Ixazomib + Lenalidomide | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | Active, not recruiting | USA | 0 |
NCT04017130 | Phase I | TAK-169 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Terminated | USA | 0 |
NCT04036461 | Phase I | CC-99712 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | Terminated | USA | ITA | FRA | ESP | CAN | 0 |
NCT04045028 | Phase I | Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Terminated | USA | 1 |
NCT04045795 | Phase I | Dexamethasone + Isatuximab + Pomalidomide | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | Completed | USA | FRA | ESP | BEL | AUS | 1 |
NCT04052880 | Phase II | Daratumumab + Ixazomib Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | Recruiting | USA | 0 |
NCT04068597 | Phase Ib/II | CCS1477 | Study to Evaluate CCS1477 in Haematological Malignancies | Recruiting | USA | SWE | GBR | FRA | ESP | 0 |
NCT04071457 | Phase III | Daratumumab + Lenalidomide + rHuPH20 Lenalidomide | S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) | Recruiting | USA | CAN | 0 |
NCT04083534 | Phase I | REGN5459 | First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT04083898 | Phase Ib/II | Bendamustine + Isatuximab + Prednisone | Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT04091126 | Phase III | Bortezomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide | Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT04093596 | Phase I | ALLO-647 + ALLO-715 ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL) | Active, not recruiting | USA | 0 |
NCT04108195 | Phase I | Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | Active, not recruiting | USA | NLD | ESP | DEU | CAN | 0 |
NCT04111107 | Phase II | Precision Medicine for Patients With Identified Actionable Mutations | Terminated | USA | 0 | |
NCT04113018 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04119336 | Phase II | Cyclophosphamide + Dexamethasone + Ixazomib + Nivolumab | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | Terminated | USA | 0 |
NCT04123418 | Phase I | WVT078 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Active, not recruiting | USA | NOR | ITA | ISR | ESP | DEU | AUS | 1 |
NCT04126200 | Phase II | belantamab mafodotin-blmf + Isatuximab belantamab mafodotin-blmf + Dostarlimab-gxly belantamab mafodotin-blmf + GSK3359609 belantamab mafodotin-blmf + Nirogacestat belantamab mafodotin-blmf belantamab mafodotin-blmf + GSK3174998 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) | Recruiting | USA | SWE | POL | NOR | NLD | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUS | 4 |
NCT04133636 | Phase II | Ciltacabtagene autoleucel | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2) | Recruiting | USA | NLD | ISR | FRA | ESP | DEU | BEL | 1 |
NCT04136756 | Phase I | NKTR-255 Daratumumab + NKTR-255 | NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma | Completed | USA | 0 |
NCT04140162 | Phase II | Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy | Active, not recruiting | USA | 0 |
NCT04142619 | Phase I | UCARTCS1A | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | Terminated | USA | 0 |
NCT04150692 | Phase II | Daratumumab | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | Withdrawn | 0 | |
NCT04150965 | Phase Ib/II | Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Active, not recruiting | USA | 0 |
NCT04151667 | Phase II | Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Lenalidomide | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04155749 | Phase I | CART-ddBCMA ACLX-001 | Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04162210 | Phase III | Dexamethasone + Pomalidomide belantamab mafodotin-blmf | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Active, not recruiting | USA | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUS | 4 |
NCT04166565 | Phase II | Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19) | Active, not recruiting | TUR | ITA | GRC | 0 |
NCT04171843 | Phase Ib/II | Cyclophosphamide + Fludarabine + PBCAR269A Cyclophosphamide + Fludarabine + Nirogacestat + PBCAR269A | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT04176380 | Phase II | RAPA-201 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | Unknown status | USA | 0 |
NCT04176718 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | Recruiting | USA | 0 |
NCT04178902 | Phase I | ABBV-467 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma | Terminated | USA | ISR | FRA | ESP | AUS | 2 |
NCT04181827 | Phase III | Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Bortezomib + Ciltacabtagene autoleucel + Cyclophosphamide + Dexamethasone + Fludarabine + Pomalidomide Ciltacabtagene autoleucel + Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + Pomalidomide | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | BEL | AUS | 2 |
NCT04184050 | Phase Ib/II | HPN217 | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM | Active, not recruiting | USA | FRA | ESP | 0 |
NCT04196491 | Phase I | Lenalidomide Cyclophosphamide + Fludarabine + Idecabtagene Vicleucel | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4) | Completed | USA | 0 |
NCT04205240 | Phase II | Cyclophosphamide + Daratumumab + Mycophenolate mofetil + Tacrolimus Fludarabine + Melphalan | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | Terminated | USA | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04214093 | Phase I | AZD0466 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Terminated | USA | 0 |
NCT04223661 | Phase II | Daratumumab + Dexamethasone + Lenalidomide | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | Withdrawn | USA | 0 |
NCT04240054 | Phase II | Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD) | Recruiting | USA | 0 |
NCT04244656 | Phase I | CTX120 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | ESP | CAN | AUS | 0 |
NCT04246047 | Phase III | belantamab mafodotin-blmf + Bortezomib + Dexamethasone Bortezomib + Daratumumab + Dexamethasone | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7) | Active, not recruiting | USA | POL | NZL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 4 |
NCT04258683 | Phase II | Bortezomib + Cyclophosphamide + Dexamethasone + Pembrolizumab | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | Withdrawn | CAN | 0 |
NCT04268199 | Phase II | Bortezomib | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE) | Recruiting | CAN | 0 |
NCT04268498 | Phase II | Carfilzomib + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | Recruiting | USA | SWE | 0 |
NCT04280328 | Phase I | CPI-444 + Daratumumab CPI-444 | Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04287855 | Phase II | Carfilzomib + Isatuximab + Pomalidomide | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | Active, not recruiting | FRA | 0 |
NCT04302324 | Phase II | Clarithromycin + Daratumumab + Dexamethasone + Pomalidomide | A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | Recruiting | USA | 0 |
NCT04309084 | Phase Ib/II | CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04318327 | Phase I | PHE885 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | ISR | AUS | 1 |
NCT04341181 | Phase II | Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) | Recruiting | DNK | 0 |
NCT04352205 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Thalidomide | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | Terminated | USA | 0 |
NCT04361851 | Phase II | Daratumumab + Pembrolizumab | Study of Dara-Pembro for Multiple Myeloma Patients | Withdrawn | 0 | |
NCT04394650 | Phase I | Cyclophosphamide + Fludarabine CC-98633 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT04398680 | Phase I | belantamab mafodotin-blmf | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13) | Recruiting | USA | GRC | 1 |
NCT04398745 | Phase I | belantamab mafodotin-blmf | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12) | Recruiting | USA | GRC | 2 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04405167 | Phase I | Tasquinimod Dexamethasone + Ixazomib + Lenalidomide + Tasquinimod | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Recruiting | USA | 0 |
NCT04407442 | Phase II | Azacitidine + Daratumumab + Dexamethasone | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | Terminated | USA | 0 |
NCT04414475 | Phase II | Bortezomib + Dexamethasone + Selinexor Dexamethasone + Pomalidomide + Selinexor Dexamethasone + Selinexor | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | Recruiting | ISR | GRC | 0 |
NCT04430894 | Phase II | Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Carfilzomib + Isatuximab + Lenalidomide Lenalidomide | KRDI in Transplant-Eligible MM | Active, not recruiting | USA | 0 |
NCT04445701 | Phase Ib/II | AO-176 AO-176 + Dexamethasone AO-176 + Bortezomib + Dexamethasone | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT04453397 | Expanded access | ABBV-383 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | No longer available | USA | 0 |
NCT04483739 | Phase III | Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia) | Active, not recruiting | NOR | NLD | ITA | GRC | ESP | DEU | CZE | 0 |
NCT04484623 | Phase III | Bortezomib + Dexamethasone + Pomalidomide belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUS | 4 |
NCT04499339 | Phase Ib/II | Anti-SLAMF7 CAR T cells | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | Active, not recruiting | FRA | ESP | DEU | 0 |
NCT04505813 | Phase Ib/II | NEXI-002 T Cells | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Suspended | USA | 0 |
NCT04513639 | Phase II | Carfilzomib + Daratumumab + Dexamethasone | The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study | Recruiting | NOR | 0 |
NCT04519476 | Phase I | Lenalidomide + Selinexor Methylprednisolone | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Recruiting | USA | 0 |
NCT04534322 | Expanded access | Dexamethasone + Melflufen | Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (sEAPort) | Approved for marketing | USA | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT04555551 | Phase I | MCARH109 | MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04557098 | Phase II | Teclistamab | A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 1 |
NCT04557150 | Phase I | RO7425781 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | Recruiting | NZL | ITA | GBR | FRA | ESP | DNK | BRA | BEL | AUS | 1 |
NCT04564703 | Phase II | Iberdomide | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | Active, not recruiting | NLD | ITA | GRC | FRA | 0 |
NCT04566328 | Phase III | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Recruiting | USA | 1 |
NCT04570631 | Phase I | ABBV-621 + Bortezomib + Dexamethasone | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 1 |
NCT04586426 | Phase I | Talquetamab-tgvs + Teclistamab | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | ESP | CAN | AUS | 2 |
NCT04613557 | Phase I | CYAD-211 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1) | Active, not recruiting | USA | BEL | 0 |
NCT04614636 | Phase I | Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 | FT538 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
NCT04634552 | Phase II | Talquetamab-tgvs | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | POL | NLD | ISR | FRA | ESP | DEU | BEL | 3 |
NCT04635189 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04635735 | Phase Ib/II | Ipilimumab | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT04643002 | Phase Ib/II | Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Isatuximab + SAR439459 | Isatuximab in Combination With Novel Agents in RRMM | Recruiting | USA | NOR | ITA | ISR | GRC | FRA | DEU | AUS | 2 |
NCT04649060 | Phase III | Daratumumab + Dexamethasone + Melflufen Daratumumab | Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma (LIGHTHOUSE) | Terminated | POL | NOR | GRC | ESP | DEU | CZE | BGR | 4 |
NCT04649359 | Phase II | Elranatamab-bcmm | Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | Active, not recruiting | USA | POL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04653246 | Phase II | Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT04656951 | Phase II | Daratumumab | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (GMMG-DADA) | Recruiting | DEU | 0 |
NCT04661137 | Phase II | Dexamethasone + Pomalidomide + Selinexor Daratumumab + Dexamethasone + Selinexor Carfilzomib + Dexamethasone + Selinexor | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT04674813 | Phase I | BMS-986393 + Cyclophosphamide + Fludarabine | A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04680468 | Phase II | belantamab mafodotin-blmf | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | Recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Active, not recruiting | 1 | |
NCT04688853 | Phase I | TEG002 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | Unknown status | USA | 0 |
NCT04700176 | Phase II | Daratumumab + Dexamethasone + Pomalidomide + Tretinoin | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | Terminated | USA | 0 |
NCT04702425 | Phase I | MIK665 + VOB560 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | Terminated | USA | ITA | ISR | FIN | ESP | BEL | 3 |
NCT04720313 | Phase I | NXC-201 | NXC-201 (Formerly HBI0101) Multiple Myeloma | Recruiting | ISR | 0 |
NCT04722146 | Phase I | Nirogacestat + Teclistamab Daratumumab + Pomalidomide + Teclistamab Bortezomib + Daratumumab + Lenalidomide + Teclistamab | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Active, not recruiting | USA | GBR | FRA | BEL | AUS | 0 |
NCT04735575 | Phase Ib/II | EMB-06 | A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma | Recruiting | AUS | 1 |
NCT04751877 | Phase III | Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients (IFM2020-05) | Active, not recruiting | FRA | 0 |
NCT04756401 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Selinexor | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04756726 | Phase Ib/II | CFT7455 CFT7455 + Dexamethasone | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |
NCT04758767 | Phase I | CID-103 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | Active, not recruiting | GBR | FRA | 0 |
NCT04764942 | Phase Ib/II | Dexamethasone + Pomalidomide + Selinexor Carfilzomib + Dexamethasone + Pomalidomide + Selinexor | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04775550 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | DARA RVD For High Risk SMM (PRISM) | Recruiting | USA | 0 |
NCT04776018 | Phase Ib/II | Mezagitamab + Subasumstat Daratumumab and hyaluronidase-fihj + Subasumstat | A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma | Terminated | USA | CAN | 0 |
NCT04776395 | Phase II | Iberdomide Dexamethasone + Iberdomide | Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | Recruiting | USA | 0 |
NCT04782687 | Phase II | Daratumumab + Dexamethasone + Lenalidomide + Selinexor | Phase II Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT04802031 | Phase II | Isatuximab | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | Withdrawn | 0 | |
NCT04802356 | Phase II | belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | Recruiting | ESP | 0 |
NCT04822337 | Phase Ib/II | belantamab mafodotin-blmf + Carfilzomib + Dexamethasone + Lenalidomide | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04824794 | Phase Ib/II | GEN3014 | GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | SWE | POL | NZL | NLD | HUN | GRC | FRA | ESP | DNK | CZE | AUS | 8 |
NCT04835129 | Phase II | Dexamethasone + Elotuzumab + Isatuximab + Pomalidomide | Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04843579 | Phase II | Clarithromycin + Dexamethasone + Pomalidomide + Selinexor | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd) | Terminated | USA | 0 |
NCT04850599 | Phase II | Carfilzomib + Isatuximab + Pomalidomide | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04855136 | Phase Ib/II | Iberdomide + Idecabtagene Vicleucel Idecabtagene Vicleucel + LY3039478 Bortezomib + Dexamethasone + Idecabtagene Vicleucel + Pomalidomide | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) | Active, not recruiting | USA | ESP | 0 |
NCT04855929 | Phase Ib/II | ANV419 | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001) | Completed | GBR | ESP | CHE | 0 |
NCT04864522 | Phase I | SLAMF7 BATs | Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs) | Withdrawn | USA | 0 |
NCT04876248 | Phase II | belantamab mafodotin-blmf + Lenalidomide | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | Recruiting | USA | 0 |
NCT04879043 | Phase Ib/II | HDP-101 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Recruiting | USA | POL | HUN | DEU | 0 |
NCT04883242 | Phase II | Carfilzomib + Dexamethasone + Isatuximab + Pomalidomide | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04891809 | Phase II | Dexamethasone + Isatuximab + Lenalidomide Dexamethasone + Lenalidomide | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged >=70 Years) With NDMM | Recruiting | GRC | AUT | 1 |
NCT04892264 | Phase Ib/II | belantamab mafodotin-blmf + Daratumumab + Lenalidomide belantamab mafodotin-blmf + Daratumumab + Dexamethasone + Lenalidomide | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | Completed | USA | 0 |
NCT04892446 | Phase II | Dexamethasone + Hu5F9-G4 + Pomalidomide Daratumumab + Hu5F9-G4 Bortezomib + Dexamethasone + Hu5F9-G4 | Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma | Completed | USA | CZE | CAN | 0 |
NCT04895410 | Phase I | Lemzoparlimab Dexamethasone + Lemzoparlimab Daratumumab + Dexamethasone + Lemzoparlimab Carfilzomib + Dexamethasone + Lemzoparlimab Dexamethasone + Lemzoparlimab + Pomalidomide | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | Terminated | USA | ISR | FRA | ESP | DEU | AUS | 1 |
NCT04896658 | Phase Ib/II | belantamab mafodotin-blmf + Cyclophosphamide + Dexamethasone | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04910568 | Phase I | Cevostamab + Tocilizumab | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | CZE | CAN | AUS | 2 |
NCT04912427 | Phase I | Bortezomib + Dexamethasone + Isatuximab | satuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | Terminated | USA | 0 |
NCT04923893 | Phase III | Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine Bortezomib + Dexamethasone + Lenalidomide | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT04925193 | Phase II | Carfilzomib + Dexamethasone + Selinexor Daratumumab + Dexamethasone + Selinexor Dexamethasone + Pomalidomide + Selinexor | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04933539 | Phase II | Carfilzomib + Daratumumab + Dexamethasone | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04934475 | Phase III | Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Melphalan | MInimal Residual Disease Adapted Strategy (MIDAS) | Active, not recruiting | FRA | BEL | 1 |
NCT04942067 | Phase Ib/II | APG-2575 + Dexamethasone + Lenalidomide APG-2575 + Dexamethasone + Pomalidomide APG-2575 + Daratumumab + Dexamethasone + Lenalidomide | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04956302 | Phase I | Bortezomib + Daratumumab and hyaluronidase-fihj + Dexamethasone + Panobinostat | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT04960579 | Phase I | P-BCMA-ALLO1 + Rimiducid | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT04973605 | Phase Ib/II | BGB-11417 + Carfilzomib + Dexamethasone BGB-11417 + Dexamethasone | Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib. | Recruiting | USA | NZL | GBR | CAN | BRA | AUS | 2 |
NCT04975399 | Phase I | CC-92328 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04975997 | Phase III | Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Iberdomide | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM). | Recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT04998786 | Phase II | Dexamethasone + Iberdomide + Ixazomib | A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03) | Active, not recruiting | FRA | 0 |
NCT05000450 | Phase Ib/II | ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT05002816 | Phase Ib/II | belantamab mafodotin-blmf + Elotuzumab | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | Recruiting | USA | 0 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05007418 | Phase I | STI-1492 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT05014412 | Phase II | Elranatamab-bcmm | MagnetisMM-9: Study of Elranatamab (PF-06863135) Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | GBR | 2 |
NCT05020236 | Phase III | Elranatamab-bcmm Daratumumab + Dexamethasone + Pomalidomide Daratumumab + Elranatamab-bcmm | MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT05027594 | Phase I | Dexamethasone + NMS-03597812 NMS-03597812 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT05028348 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Dexamethasone + Pomalidomide + Selinexor | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DEU | 0 |
NCT05032820 | Phase II | Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide | MM CAR-T to Upgrade Response | Active, not recruiting | USA | 0 |
NCT05050097 | Phase I | Lenalidomide + Talquetamab-tgvs Daratumumab + Lenalidomide + Talquetamab-tgvs Pomalidomide + Talquetamab-tgvs Carfilzomib + Talquetamab-tgvs Carfilzomib + Daratumumab + Talquetamab-tgvs | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Active, not recruiting | USA | NLD | GBR | FRA | BEL | AUS | 0 |
NCT05060627 | Phase Ib/II | belantamab mafodotin-blmf + Carfilzomib + Dexamethasone | An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | Recruiting | ESP | 0 |
NCT05064358 | Phase II | belantamab mafodotin-blmf | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14) | Active, not recruiting | USA | POL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS | ARG | 5 |
NCT05065047 | Phase I | belantamab mafodotin-blmf | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT05083169 | Phase III | Bortezomib + Daratumumab + Dexamethasone Daratumumab + Teclistamab Daratumumab + Dexamethasone + Pomalidomide | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | ARG | 5 |
NCT05090566 | Phase II | Elranatamab-bcmm + Nirogacestat | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT05091372 | Phase II | belantamab mafodotin-blmf Lenalidomide | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT05113342 | Phase Ib/II | Descartes-25 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Terminated | USA | TUR | 0 |
NCT05117008 | Phase II | belantamab mafodotin-blmf | Maintenance Belantamab Mafodotin (Blenrep) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE) | Terminated | USA | 0 |
NCT05121103 | Phase I | EZM0414 | A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Terminated | USA | 0 |
NCT05123131 | Phase II | Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD) | Recruiting | IRL | DNK | 0 |
NCT05130827 | Phase II | Plinabulin | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Active, not recruiting | USA | 0 |
NCT05137054 | Phase I | Bortezomib + Dexamethasone + Linvoseltamab Carfilzomib + Dexamethasone + Linvoseltamab Dexamethasone + Lenalidomide + Linvoseltamab Daratumumab + Dexamethasone + Linvoseltamab | REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | GRC | FRA | ESP | 0 |
NCT05139225 | Phase I | Daratumumab + TTI-622 Daratumumab + TTI-621 | A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05145400 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT05147493 | Phase II | Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab Isatuximab + Lenalidomide | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | Not yet recruiting | GRC | 0 |
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | NLD | ITA | GRC | ESP | 0 |
NCT05172596 | Phase II | PHE885 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT05177536 | Phase II | Iberdomide | Iberdomide Maintenance Therapy in Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT05182073 | Phase I | Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 | FT576 in Subjects With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05191472 | Phase II | Pembrolizumab | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | Terminated | USA | 0 |
NCT05199311 | Phase Ib/II | Carfilzomib + Dexamethasone + Iberdomide | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | Recruiting | USA | 0 |
NCT05201781 | FDA approved | Ciltacabtagene autoleucel | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Recruiting | USA | NLD | ISR | FRA | ESP | BEL | 2 |
NCT05204160 | Phase II | Pembrolizumab | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | Withdrawn | USA | 0 |
NCT05205252 | Phase Ib/II | Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) | Withdrawn | USA | 0 |
NCT05208307 | Phase II | belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | Recruiting | USA | 0 |
NCT05227144 | Phase I | ORIC-533 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT05243342 | Phase I | Daratumumab + RO7310729 | A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | Completed | NOR | ESP | DNK | AUS | 0 |
NCT05243797 | Phase III | Lenalidomide Lenalidomide + Teclistamab | A Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) | Recruiting | TUR | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 2 |
NCT05257083 | Phase III | Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6) | Recruiting | USA | SWE | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 1 |
NCT05259839 | Phase I | ABBV-383 + Dexamethasone + Pomalidomide ABBV-383 + Dexamethasone + Lenalidomide ABBV-383 + Daratumumab + Dexamethasone ABBV-383 + Nirogacestat | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | POL | ITA | ESP | DEU | AUS | 1 |
NCT05280275 | Phase Ib/II | belantamab mafodotin-blmf + Daratumumab + Dexamethasone + Lenalidomide | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | Recruiting | GRC | 0 |
NCT05289492 | Phase Ib/II | EOS-448 EOS-448 + Iberdomide Dexamethasone + EOS-448 + Iberdomide | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Terminated | USA | FRA | ESP | BEL | 0 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05298683 | Phase II | Dexamethasone + Isatuximab + Pomalidomide | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | Not yet recruiting | GRC | 0 |
NCT05308225 | Phase Ib/II | STI-6129 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05308654 | Phase I | ABBV-453 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | Active, not recruiting | USA | ISR | GBR | AUS | 0 |
NCT05317416 | Phase III | Lenalidomide Elranatamab-bcmm | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | Recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT05338775 | Phase I | Talquetamab-tgvs + Teclistamab + unspecified PD-1 antibody | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | FRA | ESP | DEU | 0 |
NCT05344833 | Phase II | Isatuximab + Lenalidomide | Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma | Recruiting | USA | 0 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05347485 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Completed | USA | 0 |
NCT05354557 | Phase II | Iberdomide | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Recruiting | USA | 0 |
NCT05363111 | Phase I | 225Ac-DOTA-Daratumumab | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT05372354 | Phase Ib/II | CC-92480 + Dexamethasone + Tazemetostat CC-92480 + Dexamethasone + Trametinib BMS986158 + CC-92480 + Dexamethasone CC-92480 + Dexamethasone | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | NOR | GBR | ESP | CAN | 0 |
NCT05391750 | Phase I | Tocilizumab + Venetoclax | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | Recruiting | USA | 0 |
NCT05392946 | Phase Ib/II | Bortezomib + Daratumumab + Dexamethasone + Iberdomide | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | Recruiting | USA | 0 |
NCT05396885 | Phase II | CART-ddBCMA | Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Recruiting | USA | 0 |
NCT05405166 | Phase III | Dexamethasone + Isatuximab + Pomalidomide | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG | 4 |
NCT05427812 | Phase Ib/II | ISB 1442 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | AUS | 1 |
NCT05431608 | Phase I | MCARH109 + MCARH125 | A Study of MCARH109 and MCARH125 in People With Multiple Myeloma | Recruiting | USA | 0 |
NCT05434689 | Phase Ib/II | Daratumumab + Dexamethasone + Iberdomide Carfilzomib + Daratumumab + Dexamethasone + Iberdomide | COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (COMMANDER) | Recruiting | USA | 0 |
NCT05438043 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide Daratumumab Carfilzomib + Daratumumab + Dexamethasone | A Study of Daratumumab | Recruiting | USA | POL | ITA | GRC | FRA | ESP | DNK | DEU | BEL | 4 |
NCT05455320 | Phase III | Daratumumab + Dexamethasone + Pomalidomide + Talquetamab-tgvs Daratumumab + Dexamethasone + Talquetamab-tgvs Dexamethasone + Pomalidomide | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | 4 |
NCT05461209 | Phase III | belantamab mafodotin-blmf Talquetamab-tgvs | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5) | Withdrawn | USA | POL | 0 |
NCT05462639 | Expanded access | Elranatamab-bcmm | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17) | No longer available | USA | CAN | 0 |
NCT05463939 | Expanded access | Teclistamab | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | Approved for marketing | 0 | |
NCT05493618 | Phase Ib/II | belantamab mafodotin-blmf + Dexamethasone + Pembrolizumab | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | Withdrawn | USA | 0 |
NCT05497804 | Phase II | Carfilzomib + Daratumumab + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | Recruiting | USA | 0 |
NCT05503550 | Expanded access | Talquetamab-tgvs | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | No longer available | SVN | ISL | BEL | 1 |
NCT05514990 | Phase Ib/II | Bortezomib + Dexamethasone + Pembrolizumab Bortezomib + Dexamethasone + Pelareorep + Pembrolizumab | Standard Doses of Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | Recruiting | USA | 0 |
NCT05519085 | Phase III | Bortezomib + Dexamethasone + Pomalidomide Bortezomib + CC-92480 + Dexamethasone | A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT05527340 | Phase II | Daratumumab + Dexamethasone + Iberdomide Dexamethasone + Iberdomide | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | Not yet recruiting | ESP | 0 |
NCT05530421 | Phase II | Dexamethasone + Selinexor + Venetoclax | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge) | Recruiting | USA | 0 |
NCT05535244 | Phase Ib/II | Cevostamab + Tocilizumab | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT05546723 | Phase I | LMY-920 | LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002) | Recruiting | USA | 0 |
NCT05552222 | Phase III | Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide + Teclistamab | A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7) | Recruiting | TUR | SWE | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 4 |
NCT05552976 | Phase III | Carfilzomib + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone | A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2) | Recruiting | USA | ROU | NOR | NLD | ITA | ISR | HUN | GRC | GBR | ESP | DNK | DEU | CAN | BRA | BGR | AUT | AUS | ARG | 9 |
NCT05556616 | Phase I | Lenalidomide + TAK-573 Pomalidomide + TAK-573 Bortezomib + TAK-573 Carfilzomib + TAK-573 Bortezomib + Pomalidomide + TAK-573 Carfilzomib + Pomalidomide + TAK-573 Carfilzomib + Daratumumab + TAK-573 Daratumumab + Pomalidomide + TAK-573 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | Completed | USA | ISR | ESP | BEL | 0 |
NCT05556798 | Phase I | belantamab mafodotin-blmf + Nirogacestat | A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | Active, not recruiting | USA | 0 |
NCT05558319 | Phase III | Bortezomib + Dexamethasone + Iberdomide + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Iberdomide + Isatuximab | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (GEM21menos65) | Not yet recruiting | ESP | 0 |
NCT05560399 | Phase I | Dexamethasone + Elotuzumab + Iberdomide | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220) | Recruiting | USA | 0 |
NCT05561387 | Phase III | Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Daratumumab and hyaluronidase-fihj Lenalidomide | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Recruiting | USA | 0 |
NCT05572229 | Phase II | Lenalidomide + Teclistamab Daratumumab + Teclistamab | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01) | Recruiting | FRA | 0 |
NCT05572515 | Phase III | Teclistamab Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT05573802 | Phase Ib/II | belantamab mafodotin-blmf + Dexamethasone + Lenalidomide + Nirogacestat | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | Recruiting | GRC | 0 |
NCT05577000 | Phase I | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05583617 | Phase Ib/II | Cevostamab + Lenalidomide + Tocilizumab | A Study Evaluating the Safety and Efficacy of Multiple Treatment Combinations in Participants With Multiple Myeloma (PLYCOM) | Recruiting | POL | FRA | ESP | AUS | 1 |
NCT05590377 | Phase Ib/II | Daratumumab + TAK-573 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | Completed | USA | FRA | ESP | CAN | AUS | 2 |
NCT05623020 | Phase III | Daratumumab + Elranatamab-bcmm + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6) | Recruiting | POL | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CAN | AUS | 3 |
NCT05641324 | Phase I | ANV419 + Dexamethasone + Lenalidomide ANV419 + Daratumumab ANV419 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | Terminated | FRA | ESP | DNK | DEU | CHE | 0 |
NCT05646836 | Phase I | Cevostamab + Tocilizumab Cevostamab + RO7310729 + Tocilizumab | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | NOR | ISR | GRC | ESP | DNK | AUS | 1 |
NCT05650632 | Phase I | ABBV-383 | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | GBR | FRA | ESP | DNK | CAN | 0 |
NCT05651932 | Phase I | KTX-1001 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05652335 | Phase I | JNJ-79635322 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | NLD | GBR | FRA | ESP | BEL | 1 |
NCT05665140 | Phase II | Lenalidomide Isatuximab Bortezomib + Dexamethasone + Lenalidomide | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS) | Recruiting | DEU | 0 |
NCT05666700 | Phase I | Ciltacabtagene autoleucel | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL) | Recruiting | AUS | 0 |
NCT05675319 | Phase III | Bortezomib + Daratumumab + Dexamethasone Carfilzomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide Bortezomib + Dexamethasone + Pomalidomide Dexamethasone + Ixazomib + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM) | Recruiting | DEU | 0 |
NCT05675449 | Phase I | Carfilzomib + Elranatamab-bcmm | A Clinical Trial of Three Medicines (Elranatamab Plus Carfilzomib and Dexamethasone) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20) | Recruiting | USA | ISR | 0 |
NCT05690984 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Elimination of Minimal Residual Disease After Transplant (EMAT) | Recruiting | USA | 0 |
NCT05695508 | Phase II | Daratumumab + Dexamethasone + Lenalidomide + Teclistamab Daratumumab + Lenalidomide + Teclistamab Bortezomib + Daratumumab + Dexamethasone + Lenalidomide + Teclistamab | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX) | Recruiting | DEU | 0 |
NCT05698303 | Phase I | CT103A | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT05698888 | Phase I | VP301 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Terminated | USA | 0 |
NCT05704049 | Phase II | Carfilzomib + Dexamethasone + Isatuximab | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | GRC | CZE | BRA | AUS | 2 |
NCT05714839 | Phase I | Belantamab Belantamab + belantamab mafodotin-blmf + Dexamethasone + Lenalidomide belantamab mafodotin-blmf | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) | Recruiting | TUR | POL | GBR | BRA | AUS | ARG | 3 |
NCT05722418 | Phase I | CB-011 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage) | Recruiting | USA | 0 |
NCT05730036 | Phase III | Linvoseltamab Dexamethasone + Elotuzumab + Pomalidomide | A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidomide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | Recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 4 |
NCT05776979 | Phase II | Isatuximab + Lenalidomide | Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | Recruiting | USA | 0 |
NCT05789303 | Phase II | belantamab mafodotin-blmf + Carfilzomib + Dexamethasone + Pomalidomide | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | Recruiting | USA | 0 |
NCT05801939 | Phase II | Cevostamab | Cevostamab Following CAR T Cell Therapy for RRMM | Recruiting | USA | 0 |
NCT05804032 | Phase III | Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | Recruiting | DEU | AUT | 0 |
NCT05820763 | Phase II | Dexamethasone + Lenalidomide + Selinexor Lenalidomide + Selinexor | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | Withdrawn | 0 | |
NCT05823571 | Phase I | Itacitinib | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Recruiting | USA | 0 |
NCT05827016 | Phase III | Lenalidomide Iberdomide | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT05828511 | Phase Ib/II | Linvoseltamab | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment. (LINKER-MM4) | Recruiting | USA | FRA | ESP | 0 |
NCT05839626 | Phase Ib/II | SAR445514 | A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) | Recruiting | ITA | HUN | GBR | ESP | CZE | BEL | AUS | 0 |
NCT05841550 | Phase Ib/II | QS21 + TG01 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | Recruiting | NOR | 0 |
NCT05847569 | Phase II | belantamab mafodotin-blmf | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT05849610 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL) | Recruiting | ESP | 0 |
NCT05850234 | Phase Ib/II | GC012F | A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT05853965 | Phase Ib/II | belantamab mafodotin-blmf + Venetoclax | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (BELI(E)VE) | Recruiting | DEU | 0 |
NCT05862012 | Phase I | ISB 2001 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | AUS | 1 |
NCT05874193 | Phase II | belantamab mafodotin-blmf | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed Refractory Myeloma (COSTA) | Not yet recruiting | USA | 0 |
NCT05889221 | Phase II | Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | Active, not recruiting | FRA | 0 |
NCT05896228 | Phase II | Iberdomide Carfilzomib + Daratumumab + Dexamethasone + Iberdomide | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd) | Recruiting | USA | 0 |
NCT05908396 | Phase I | IGM-2644 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT05908409 | Phase Ib/II | IDP-121 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | ESP | 0 |
NCT05911321 | Phase II | Dexamethasone + Isatuximab + Pomalidomide | Isa-Pom-Dex in Elderly/Frail Subjects With RRMM | Recruiting | USA | 0 |
NCT05918250 | Phase I | mRNA-2736 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Withdrawn | USA | CAN | 0 |
NCT05922501 | Phase II | belantamab mafodotin-blmf + Dexamethasone + Isatuximab + Pomalidomide | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA) | Not yet recruiting | USA | 0 |
NCT05927571 | Phase I | Cevostamab + Elranatamab-bcmm Tocilizumab | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | Recruiting | ISR | AUS | 1 |
NCT05972135 | Phase II | Teclistamab + Tocilizumab | Outpatient Administration of Teclistamab for Multiple Myeloma | Recruiting | USA | 0 |
NCT05981209 | Phase I | CC-92480 + Dexamethasone + Elotuzumab | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | Recruiting | USA | 0 |
NCT06042725 | Phase I | Daratumumab + Dexamethasone + Lenalidomide + Venetoclax Daratumumab + Dexamethasone + Venetoclax Dexamethasone + Lenalidomide + Venetoclax | Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | Recruiting | USA | 0 |
NCT06045806 | Phase III | Idecabtagene Vicleucel + Lenalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) | Active, not recruiting | USA | ROU | POL | NOR | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 2 |
NCT06048250 | Phase I | CC-92480 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | Recruiting | USA | 0 |
NCT06050512 | Phase Ib/II | CC-92480 + Dexamethasone + Ixazomib | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Recruiting | 0 | |
NCT06055075 | Phase I | Carfilzomib + RO7425781 Daratumumab + RO7425781 RO7425781 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | NZL | ITA | FRA | ESP | DNK | DEU | CAN | BRA | AUS | 1 |
NCT06057402 | FDA approved | Elranatamab-bcmm | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15) | Recruiting | USA | FRA | CAN | AUS | 1 |
NCT06066346 | Phase II | Talquetamab-tgvs | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | Recruiting | USA | 0 |
NCT06066359 | Phase Ib/II | Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK | Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06083207 | Phase Ib/II | IBI3003 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | AUS | 1 |
NCT06087653 | Phase Ib/II | Bortezomib + Dexamethasone + Lenalidomide | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT06105554 | Phase Ib/II | Belumosudil mesylate | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06106945 | Phase Ib/II | AZD0305 | A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | CAN | AUS | 2 |
NCT06107738 | Phase II | Daratumumab + Iberdomide | Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma (IBEX) | Recruiting | USA | 0 |
NCT06119685 | Phase Ib/II | IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Recruiting | USA | 0 |
NCT06121843 | Phase I | BMS-986393 + Iberdomide BMS-986393 + CC-92480 BMS-986393 + CC-93269 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT06138275 | Phase II | Elranatamab-bcmm | Elranatamab in R/R Multiple Myeloma | Recruiting | USA | 0 |
NCT06152575 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide Elranatamab-bcmm | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Recruiting | USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | ARG | 1 |
NCT06153251 | Phase I | BMS-986453 Cyclophosphamide + Fludarabine | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | 0 |
NCT06158841 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Selinexor ABBV-383 | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | SWE | POL | ITA | ISR | HUN | GRC | FRA | ESP | DNK | DEU | BEL | AUT | AUS | 6 |
NCT06163898 | Phase Ib/II | CC-93269 CC-92480 + CC-93269 + Dexamethasone | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | USA | ISR | 0 |
NCT06169215 | Phase II | Bortezomib + Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab and hyaluronidase-fihj Bortezomib + Daratumumab + Dexamethasone + Selinexor Bortezomib + Daratumumab and hyaluronidase-fihj + Dexamethasone + Selinexor | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT06171685 | Phase II | Teclistamab | MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM | Recruiting | USA | 0 |
NCT06179888 | Phase II | Iberdomide | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Recruiting | USA | 0 |
NCT06182774 | Phase III | Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma | Recruiting | CAN | 0 |
NCT06187441 | Phase III | Daratumumab + Dexamethasone + Lenalidomide | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM) | Recruiting | NLD | 0 |
NCT06189833 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS) | Recruiting | NLD | ITA | GRC | DEU | AUT | 0 |
NCT06203912 | Phase I | Cyclophosphamide Dexamethasone Isatuximab + TGF-beta-imprinted NK cells | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06207799 | Phase II | Elranatamab-bcmm | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | Recruiting | USA | 0 |
NCT06208150 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Talquetamab-tgvs + Teclistamab Pomalidomide + Talquetamab-tgvs Dexamethasone | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT06215118 | Phase I | Elranatamab-bcmm + Iberdomide | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | Recruiting | USA | CAN | 0 |
NCT06216158 | Phase III | Iberdomide Iberdomide + Isatuximab Dexamethasone | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | Recruiting | DEU | 0 |
NCT06223516 | Phase I | ABBV-383 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | DEU | 1 |
NCT06232707 | Phase III | Carfilzomib Pomalidomide Elotuzumab Dexamethasone Daratumumab CC-93269 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE) | Withdrawn | USA | TUR | SWE | ROU | NOR | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT06271252 | Phase I | OriCAR-017 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | Recruiting | USA | 0 |
NCT06282978 | Phase II | Elranatamab-bcmm | Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | Recruiting | ESP | 0 |
NCT06297226 | Phase II | BMS-986393 | Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) | Recruiting | USA | CAN | 1 |
NCT06304636 | Phase I | Descartes-15 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01) | Recruiting | USA | 0 |
NCT06348108 | Phase I | Dexamethasone + Iberdomide + Talquetamab-tgvs | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT06348147 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | Not yet recruiting | USA | 0 |
NCT06351644 | Phase Ib/II | Dexamethasone + Narazaciclib | ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06353022 | Phase II | Talquetamab-tgvs + Teclistamab Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Lenalidomide + Teclistamab | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01) | Not yet recruiting | FRA | 0 |
NCT06376526 | Phase II | Linvoseltamab | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT) | Recruiting | USA | 0 |
NCT06381141 | Phase I | CLN-619 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06411301 | Phase I | RYZ101 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS) | Not yet recruiting | BEL | 0 |
NCT06413498 | Phase III | Cyclophosphamide + Fludarabine Carfilzomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide CART-ddBCMA Carfilzomib + Dexamethasone | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3) | Recruiting | USA | 0 |
NCT06421675 | Phase II | Elranatamab-bcmm | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE) | Not yet recruiting | CAN | 0 |
NCT06425991 | Phase I | Teclistamab | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT06433947 | Phase I | OPN-6602 Dexamethasone + OPN-6602 | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06461988 | Phase II | Lenalidomide + Talquetamab-tgvs Talquetamab-tgvs | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT06465316 | Phase I | Iberdomide + Teclistamab | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06505369 | Phase II | Talquetamab-tgvs Teclistamab Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC) | Recruiting | NOR | EST | DNK | 0 |
NCT06517017 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma (UltraFrailMM) | Not yet recruiting | USA | 0 |
NCT06518551 | Phase Ib/II | Dexamethasone + Elotuzumab + Iberdomide | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | Not yet recruiting | USA | 0 |
NCT06523621 | Phase II | Nivolumab | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | Not yet recruiting | USA | 0 |
NCT06536413 | Phase Ib/II | Carfilzomib + Dexamethasone + Tretinoin | ATRA and Carfilzomib in Plasma Cell Myeloma Patients (ATRA) | Recruiting | USA | 0 |
NCT06550895 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Talquetamab-tgvs | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (MonumenTAL-8) | Recruiting | USA | AUS | 0 |
NCT06572605 | Phase Ib/II | Talquetamab-tgvs | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease | Not yet recruiting | USA | 0 |
NCT06577025 | Phase II | Ciltacabtagene autoleucel Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Talquetamab-tgvs Daratumumab + Teclistamab | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition) | Recruiting | USA | BRA | AUS | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06588660 | Phase I | ST-067 + Teclistamab | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT06615479 | Phase III | Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide BMS-986393 + Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide Cyclophosphamide + Fludarabine | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2) | Not yet recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT06623630 | Phase I | Ciltacabtagene autoleucel + Cyclophosphamide | Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | Not yet recruiting | USA | 0 |
NCT06630806 | Phase Ib/II | SAR446523 | A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma | Recruiting | AUS | 0 |
NCT06679829 | Phase II | Melphalan Melphalan + Siltuximab | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | Recruiting | USA | 0 |